AU2021251087A1 - Anti-TMPRSS6 antibodies and uses thereof - Google Patents

Anti-TMPRSS6 antibodies and uses thereof Download PDF

Info

Publication number
AU2021251087A1
AU2021251087A1 AU2021251087A AU2021251087A AU2021251087A1 AU 2021251087 A1 AU2021251087 A1 AU 2021251087A1 AU 2021251087 A AU2021251087 A AU 2021251087A AU 2021251087 A AU2021251087 A AU 2021251087A AU 2021251087 A1 AU2021251087 A1 AU 2021251087A1
Authority
AU
Australia
Prior art keywords
seq
tmprss6
antibody
amino acid
substantially identical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021251087A
Other languages
English (en)
Inventor
Buxin CHEN
Xin Du
Yu Jean WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mabwell Therapeutics Inc
Original Assignee
Mabwell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabwell Therapeutics Inc filed Critical Mabwell Therapeutics Inc
Publication of AU2021251087A1 publication Critical patent/AU2021251087A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2021251087A 2020-04-07 2021-04-05 Anti-TMPRSS6 antibodies and uses thereof Pending AU2021251087A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063006695P 2020-04-07 2020-04-07
US63/006,695 2020-04-07
US202163158265P 2021-03-08 2021-03-08
US63/158,265 2021-03-08
PCT/US2021/025775 WO2021207072A1 (en) 2020-04-07 2021-04-05 Anti-tmprss6 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2021251087A1 true AU2021251087A1 (en) 2022-12-01

Family

ID=75888147

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021251087A Pending AU2021251087A1 (en) 2020-04-07 2021-04-05 Anti-TMPRSS6 antibodies and uses thereof

Country Status (9)

Country Link
US (3) US12215170B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126220A1 (cg-RX-API-DMAC7.html)
JP (2) JP7813234B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230007368A (cg-RX-API-DMAC7.html)
CN (1) CN115243762B (cg-RX-API-DMAC7.html)
AU (1) AU2021251087A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174339A1 (cg-RX-API-DMAC7.html)
TW (1) TW202204422A (cg-RX-API-DMAC7.html)
WO (1) WO2021207072A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
US20230295345A1 (en) * 2020-04-07 2023-09-21 Mabwell Therapeutics, Inc. Anti-tmprss6 antibodies and uses thereof
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
KR20250128393A (ko) * 2022-11-25 2025-08-27 맵웰 테라퓨틱스 인크. 항-tmprss6 항체 및 그의 용도
CN120936629A (zh) * 2023-04-04 2025-11-11 迪斯克医药公司 抗tmprss6抗体及其用途
WO2024211900A1 (en) * 2023-04-06 2024-10-10 Memorial Sloan-Kettering Cancer Center Il-10 receptor antibodies and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
WO2005023835A2 (en) 2003-09-09 2005-03-17 Irm Llc Modulators of transmembrane protease serine 6
GB0614201D0 (en) 2006-07-18 2006-08-23 Univ Cardiff Matriptase-2
PE20130588A1 (es) 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
EP2776564B1 (en) * 2011-11-07 2019-10-02 Ionis Pharmaceuticals, Inc. Modulation of tmprss6 expression
AR093620A1 (es) * 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
CN106062004A (zh) 2013-12-17 2016-10-26 科马布有限公司 人靶标
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
AU2016302768B2 (en) * 2015-07-31 2019-08-22 Medimmune Limited Methods for treating hepcidin-mediated disorders
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
EP4065607A1 (en) 2019-11-29 2022-10-05 Kymab Limited Treatment for physiological iron overload
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
CA3216106A1 (en) 2021-04-26 2022-11-03 Alnylam Pharmaceuticals, Inc. Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
WO2022229150A1 (en) 2021-04-27 2022-11-03 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treawtment of myeloproliferative disorders

Also Published As

Publication number Publication date
KR20230007368A (ko) 2023-01-12
EP4126220A1 (en) 2023-02-08
CN115243762B (zh) 2026-07-28
WO2021207072A1 (en) 2021-10-14
JP2026089058A (ja) 2026-05-29
CN115243762A (zh) 2022-10-25
JP7813234B2 (ja) 2026-02-12
US11866513B2 (en) 2024-01-09
CA3174339A1 (en) 2021-10-14
US20230203196A1 (en) 2023-06-29
TW202204422A (zh) 2022-02-01
JP2023520969A (ja) 2023-05-23
US12215170B2 (en) 2025-02-04
US20250304719A1 (en) 2025-10-02
US20230348623A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US11866513B2 (en) Anti-TMPRSS6 antibodies and uses thereof
EP2997042B1 (en) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
CN106459215B (zh) 治疗自身免疫疾病的结合fcrn的抗体
EP2536761B1 (en) Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
US20240002488A1 (en) Method of treating or preventing liver conditions
RU2744909C2 (ru) Способ лечения или предотвращения инсульта
CA2769409A1 (en) Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
RU2718054C2 (ru) Способ лечения нефропатии
US20230295345A1 (en) Anti-tmprss6 antibodies and uses thereof
US10975159B2 (en) Compounds binding human CD160 and uses thereof
US20250136718A1 (en) Anti-tmprss6 antibodies and uses thereof
JP2025512137A (ja) 抗mica/b抗体及びその使用
AU2023384147A1 (en) Anti-tmprss6 antibodies and uses thereof
HK40079278A (en) Anti-tmprss6 antibodies and uses thereof
CN118078985A (zh) 抗tmprss6抗体及其用途
HK40104812A (en) Anti-tmprss6 antibodies and uses thereof
RU2790023C2 (ru) Способы лечения заболевания с применением ингибиторов костного морфогенетического белка 6 (вмр6)
CN120936629A (zh) 抗tmprss6抗体及其用途